Multiple Sclerosis Clinical Trial
— POTOMSOfficial title:
Power Training in Older Multiple Sclerosis Patients
The study seeks to investigate whether 24 weeks of power training has neuroprotective effects in older PwMS. Additional purposes are to examine the effects of 24 weeks power training on physical function, cognitive function and neuromuscular function. Further, it is investigated whether the potential effects of power training are maintained after 24 weeks of follow-up.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | August 28, 2024 |
Est. primary completion date | August 28, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - = 60 years of age. - Clinically diagnosed with MS according to the McDonald criteria (48). - Having an EDSS = 6.5. - able to transport themselves to the testing at Aarhus University and Aarhus University Hospital. - able to transport themselves to training, if randomized to the PRP group. Exclusion Criteria: - having comorbidities (cardiovascular, respiratory, orthopedic, or other neurological diseases than MS) affecting PRP participation or MRI scans. - having a pacemaker. - having metallic implant(s) that prevents MRI scans. - having untreated osteoporosis; t-score below -2.5 and a history of low energy facture or t-score below -3.0. - participating in more than two sessions per week of structured PRE and have done so for the past 3 months. - Are cognitively impaired at a level expected to prevent the participant from understanding training and testing instructions. |
Country | Name | City | State |
---|---|---|---|
Denmark | Tobias Gæmelke | Aarhus C |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus | University of Copenhagen, University of Southern Denmark |
Denmark,
Aagaard P, Suetta C, Caserotti P, Magnusson SP, Kjaer M. Role of the nervous system in sarcopenia and muscle atrophy with aging: strength training as a countermeasure. Scand J Med Sci Sports. 2010 Feb;20(1):49-64. doi: 10.1111/j.1600-0838.2009.01084.x. — View Citation
Best JR, Chiu BK, Liang Hsu C, Nagamatsu LS, Liu-Ambrose T. Long-Term Effects of Resistance Exercise Training on Cognition and Brain Volume in Older Women: Results from a Randomized Controlled Trial. J Int Neuropsychol Soc. 2015 Nov;21(10):745-56. doi: 10.1017/S1355617715000673. — View Citation
Bottaro M, Machado SN, Nogueira W, Scales R, Veloso J. Effect of high versus low-velocity resistance training on muscular fitness and functional performance in older men. Eur J Appl Physiol. 2007 Feb;99(3):257-64. doi: 10.1007/s00421-006-0343-1. Epub 2006 Dec 5. — View Citation
Caserotti P, Aagaard P, Larsen JB, Puggaard L. Explosive heavy-resistance training in old and very old adults: changes in rapid muscle force, strength and power. Scand J Med Sci Sports. 2008 Dec;18(6):773-82. doi: 10.1111/j.1600-0838.2007.00732.x. Epub 2008 Jan 30. — View Citation
Earles DR, Judge JO, Gunnarsson OT. Velocity training induces power-specific adaptations in highly functioning older adults. Arch Phys Med Rehabil. 2001 Jul;82(7):872-8. doi: 10.1053/apmr.2001.23838. — View Citation
Henwood TR, Riek S, Taaffe DR. Strength versus muscle power-specific resistance training in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2008 Jan;63(1):83-91. doi: 10.1093/gerona/63.1.83. — View Citation
Hurwitz BJ. Analysis of current multiple sclerosis registries. Neurology. 2011 Jan 4;76(1 Suppl 1):S7-13. doi: 10.1212/WNL.0b013e31820502f6. — View Citation
Hvid LG, Strotmeyer ES, Skjodt M, Magnussen LV, Andersen M, Caserotti P. Voluntary muscle activation improves with power training and is associated with changes in gait speed in mobility-limited older adults - A randomized controlled trial. Exp Gerontol. 2016 Jul;80:51-6. doi: 10.1016/j.exger.2016.03.018. Epub 2016 Apr 14. — View Citation
Liu-Ambrose T, Nagamatsu LS, Graf P, Beattie BL, Ashe MC, Handy TC. Resistance training and executive functions: a 12-month randomized controlled trial. Arch Intern Med. 2010 Jan 25;170(2):170-8. doi: 10.1001/archinternmed.2009.494. — View Citation
Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008 Sep;14(8):1091-8. doi: 10.1177/1352458508092263. — View Citation
Reid KF, Martin KI, Doros G, Clark DJ, Hau C, Patten C, Phillips EM, Frontera WR, Fielding RA. Comparative effects of light or heavy resistance power training for improving lower extremity power and physical performance in mobility-limited older adults. J Gerontol A Biol Sci Med Sci. 2015 Mar;70(3):374-80. doi: 10.1093/gerona/glu156. Epub 2014 Sep 8. — View Citation
Schoenfeld BJ, Contreras B, Willardson JM, Fontana F, Tiryaki-Sonmez G. Muscle activation during low- versus high-load resistance training in well-trained men. Eur J Appl Physiol. 2014 Dec;114(12):2491-7. doi: 10.1007/s00421-014-2976-9. Epub 2014 Aug 12. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Normalized gray and white matter volume change. | MRI scan. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Volume of the brain nucleis: thalamus, hippocampus, putamen, caudate, globus pallidus, corticospinal tract, cingulate gyrus, corpus callosum, cervical spinal volume, motor cortex | MRI scan. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Diffusivity of the brain nucleis: thalamus, hippocampus, putamen, caudate, globus pallidus, corticospinal tract, cingulate gyrus, corpus callosum, cervical spinal volume, motor cortex | DTI scan. | Baseline, after 24 weeks and after 48 weeks. | |
Other | White matter fibre orientations | MKI scan. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Glial fibrillary acidic protein (GFAP) change. | Resting blood sample- Marker of neurodegeneration. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Neurofilament light chain (NfL) change. | Resting blood sample-Marker of neurodegeneration: | Baseline, after 24 weeks and after 48 weeks. | |
Other | Brain-derived neurotrophic factor (BDNF) change. | Resting blood sample-Neurotrophic factor. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Insulin-like growth factor-1 (IGF). | Resting blood sample-Neurotrophic factor. | Baseline, after 24 weeks and after 48 weeks. | |
Other | C-reactive protein (CRP) change. | Resting blood sample-Inflammatory markers. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Interleukin-6 (IL-6) change. | Resting blood sample-Inflammatory markers. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Tumor necrosis alpha (TNF-alpha) change. | Resting blood sample-Inflammatory markers. | Baseline, after 24 weeks and after 48 weeks. | |
Other | C-terminal collagen cross-links (CTX) change. | Resting blood sample- Bone turnover markers. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Type-1n-terminal propeptide (P1NP) change. | Resting blood sample- Bone turnover markers. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Bone mineral density of the femoral neck and lumbar spine change. | Dexa scan. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Body composition change. | Dexa scan- whole body scan. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Cognition change . | Selective Reminding Test (memory) and Symbol Digit Modalities Test (processing speed). | Baseline, after 24 weeks and after 48 weeks. | |
Other | Nine step stair test change. | Time to climb a 9 step flight of stairs. | Baseline, after 24 weeks and after 48 weeks | |
Other | Six Spot Step Test (SSST) change. | SSST is a measure of walking ability, balance and coordination. Measured as the time to complete the course. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Six-minute walk test (&MWT) change. | Distance covered on a 30 meter track during six minutes maximal walking. Distance covered each minute is noted. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Timed 25-Feet Walk Test (T25FWT) change. | Time to walk 25 feet (normal walk and maximal walk pace). | Baseline, after 24 weeks and after 48 weeks. | |
Other | Short Physical performance battery change. | Composite score from Five Times Sit- to- Stand Test, Tandem Test and 3 meter walk test. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Maximal Voluntary Contraction (MVC) change. | The following muscle groups are tested: Knee flexors, Knee extensors, Plantar flexor and Dorsal flexor. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Rate of force development (RFD) change. | The following muscle groups are tested: Knee flexors, Knee extensors, Plantar flexor and Dorsal flexor. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Dynamic Strength change. | The following muscle groups are tested: Knee flexors, Knee extensors, Plantar flexor and Dorsal flexor. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Force Steadiness change. | Unilateral leg press | Baseline, after 24 weeks and after 48 weeks. | |
Other | Voluntary activation | Interpolated twitch technique applied on the quadriceps muscle | Baseline, after 24 weeks and after 48 weeks. | |
Other | Electromyography (EMG) | The following muscle groups are tested: Knee flexors, Knee extensors, Plantar flexor and Dorsal flexor. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Grip strength change. | Measured by Hand Dynamoter. | Baseline, after 24 weeks and after 48 weeks. | |
Other | SF-12 change. | Patient Reported Outcome Measure. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Pittsburg Sleep Qulity Index change. | Patient Reported Outcome Measure. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Brief pain inventory change. | Patient Reported Outcome Measure. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Baecke Physical Activity change. | Patient Reported Outcome Measure. | Baseline, after 24 weeks and after 48 weeks. | |
Other | HADS change. | Patient Reported Outcome Measure. | Baseline, after 24 weeks and after 48 weeks. | |
Other | EQ-5D change. | Patient Reported Outcome Measure. | Baseline, after 24 weeks and after 48 weeks. | |
Other | FES-I change. | Patient Reported Outcome Measure. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Multiple Sclerosis Impact Scale (MSIS-29) change. | Patient Reported Outcome Measure (only applicable for people with MS). | Baseline, after 24 weeks and after 48 weeks . | |
Other | Modified Fatigue Impact Scale (MFIS) change. | Patient Reported Outcome Measure (only applicable for people with MS). | Baseline, after 24 weeks and after 48 weeks . | |
Other | 12-Item MS walking Scale (MSWS-12) change. | Patient Reported Outcome Measure (only applicable for people with MS). | Baseline, after 24 weeks and after 48 weeks . | |
Other | Expanded Disability Status Scale (only applicable for people with MS). | The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a trained exercise physiologist. | Baseline, after 24 weeks and after 48 weeks. | |
Other | Nine hole peg test | Manual dexterity and upper body function | Baseline, after 24 weeks and after 48 weeks. | |
Other | Physical activity | Accelerometry (7 days ware time) | Baseline, after 24 weeks and after 48 weeks. | |
Primary | Percentage brain volume change. | Whole brain atrophy will be measured from MRI-scans. | Baseline, after 24 weeks and after 48 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |